GRP55 - G-Protein Coupled Receptor 55 | Elisa - Clia - Antibody - Protein

Background:

GPR55 is a G protein-coupled receptor belonging to the class A (rhodopsin-like) family of GPCRs. GPR55 was identified in the early 2000s through bioinformatics and molecular cloning techniques.GPR55 is expressed in various tissues and organs, including the brain, immune cells, gastrointestinal tract, and peripheral tissues. GPR55 has been implicated in mediating the effects of various endogenous and exogenous ligands, including lysophosphatidylinositol (LPI), cannabinoids, and certain lipid metabolites.In summary, GPR55 is a G protein-coupled receptor with diverse expression patterns and potential roles in neurological function, immune modulation, and metabolic regulation. While its exact physiological functions and signaling mechanisms are still being elucidated, GPR55 represents a promising target for therapeutic intervention in a range of diseases.

Physiological Functions:

• Endocannabinoid System: GPR55 has been proposed as a putative cannabinoid receptor, although its classification within the endocannabinoid system is still debated.
• Neurological Functions: GPR55 is expressed in the brain and has been implicated in the regulation of neuronal signaling, neurotransmitter release, and neuroinflammation. It may play a role in modulating pain perception, motor function, and cognition.
• Immune Modulation: GPR55 activation has been shown to modulate immune responses, including cytokine production, leukocyte migration, and inflammatory processes, suggesting a potential role in immune regulation.

Clinical Implications:

• Neurological Disorders: GPR55 dysregulation has been implicated in neurological disorders such as epilepsy, neuropathic pain, multiple sclerosis, and neuroinflammation, suggesting potential therapeutic implications.
• Cancer: GPR55 has been associated with tumor growth, metastasis, and angiogenesis in certain cancers, making it a potential target for cancer therapy.
• Metabolic Disorders: GPR55 has been implicated in the regulation of metabolic processes, including glucose metabolism, insulin sensitivity, and lipid metabolism, suggesting potential implications for metabolic disorders such as obesity and diabetes.

Therapeutic Potential:

• Drug Development: GPR55 agonists and antagonists are being investigated for their therapeutic potential in various diseases, including neurological disorders, cancer, and metabolic disorders.
• Precision Medicine: Targeting GPR55 signaling pathways may offer personalized treatment strategies for individuals with conditions associated with dysregulated neuronal function, immune responses, or metabolic abnormalities.